Previous studies based on tumoroids guided the selection of a combination treatment consisting of the KRAS-selective inhibitor AMG501 and EGFR inhibitor cetuximab for CRC organoids with KRASG12C mutation rather than single KRAS inhibitor exposure [113], the combination of the FGFR inhibitor BGJ398 and the mitogen-activated protein kinase inhibitor trametinib for FGFR1-aberrant NSCLC organoids instead of the combination of BGJ398 and PI3K inhibitor BKM120 [24], and combination treatment with MC3138 (a SIRT5 activator) and gemcitabine for patients with PDAC harboring low SIRT5 expression [176]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.